Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 104

    1.

    Therapeutic amprenavir concentrations in cerebrospinal fluid.

    Croteau D, Letendre S, Best BM, Rossi SS, Ellis RJ, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur J, McCutchan JA, Morgello S, Simpson DM, Way L, Capparelli E, Grant I; CHARTER Group.

    Antimicrob Agents Chemother. 2012 Apr;56(4):1985-9. Epub 2012 Jan 30.

    PMID:
    22290964
    [PubMed - in process]
    2.

    Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives.

    Ordonez P, Hamasaki T, Isono Y, Sakakibara N, Ikejiri M, Maruyama T, Baba M.

    Antimicrob Agents Chemother. 2012 May;56(5):2581-9. Epub 2012 Jan 30.

    PMID:
    22290950
    [PubMed - in process]
    3.

    Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1.

    Clouser CL, Holtz CM, Mullett M, Crankshaw DL, Briggs JE, O'Sullivan MG, Patterson SE, Mansky LM.

    Antimicrob Agents Chemother. 2012 Apr;56(4):1942-8. Epub 2012 Jan 23.

    PMID:
    22271861
    [PubMed - in process]
    4.

    A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients.

    Smythe W, Khandelwal A, Merle C, Rustomjee R, Gninafon M, Bocar Lo M, Sow OB, Olliaro PL, Lienhardt C, Horton J, Smith P, McIlleron H, Simonsson US.

    Antimicrob Agents Chemother. 2012 Apr;56(4):2091-8. Epub 2012 Jan 17.

    PMID:
    22252827
    [PubMed - in process]
    5.

    Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy.

    Ananworanich J, Gorowara M, Avihingsanon A, Kerr SJ, van Heesch N, Khongpetch C, Uanithirat A, Hill A, Ruxrungtham K, Burger DM; HIV-NAT 127 Study Team.

    Antimicrob Agents Chemother. 2012 Apr;56(4):1892-8. Epub 2012 Jan 17.

    PMID:
    22252825
    [PubMed - in process]
    6.

    Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.

    Henrich TJ, Lewine NR, Lee SH, Rao SS, Berro R, Gulick RM, Moore JP, Tsibris AM, Kuritzkes DR.

    Antimicrob Agents Chemother. 2012 Apr;56(4):1931-5. Epub 2012 Jan 17.

    PMID:
    22252820
    [PubMed - in process]
    7.

    Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptase.

    Kirby KA, Marchand B, Ong YT, Ndongwe TP, Hachiya A, Michailidis E, Leslie MD, Sietsema DV, Fetterly TL, Dorst CA, Singh K, Wang Z, Parniak MA, Sarafianos SG.

    Antimicrob Agents Chemother. 2012 Apr;56(4):2048-61. Epub 2012 Jan 17.

    PMID:
    22252812
    [PubMed - in process]
    8.

    Preexposure prophylaxis with albumin-conjugated C34 peptide HIV-1 fusion inhibitor in SCID-hu Thy/Liv mice.

    Stoddart CA, Nault G, Galkina SA, Bousquet-Gagnon N, Bridon D, Quraishi O.

    Antimicrob Agents Chemother. 2012 Apr;56(4):2162-5. Epub 2012 Jan 17.

    PMID:
    22252805
    [PubMed - in process]
    Free PMC Article
    9.

    Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity.

    Sohl CD, Singh K, Kasiviswanathan R, Copeland WC, Mitsuya H, Sarafianos SG, Anderson KS.

    Antimicrob Agents Chemother. 2012 Mar;56(3):1630-4. Epub 2011 Dec 12.

    PMID:
    22155823
    [PubMed - in process]
    10.

    Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings.

    Johnson TJ, Srinivasan P, Albright TH, Watson-Buckheit K, Rabe L, Martin A, Pau CP, Hendry RM, Otten R, McNicholl J, Buckheit R Jr, Smith J, Kiser PF.

    Antimicrob Agents Chemother. 2012 Mar;56(3):1291-9. Epub 2011 Dec 12.

    PMID:
    22155820
    [PubMed - in process]
    11.

    Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.

    Gonzalez-Serna A, McGovern RA, Harrigan PR, Vidal F, Poon AF, Ferrando-Martinez S, Abad MA, Genebat M, Leal M, Ruiz-Mateos E.

    Antimicrob Agents Chemother. 2012 Mar;56(3):1202-7. Epub 2011 Dec 5.

    PMID:
    22143533
    [PubMed - in process]
    12.

    Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.

    Vourvahis M, Langdon G, Labadie RR, Layton G, Ndongo MN, Banerjee S, Davis J.

    Antimicrob Agents Chemother. 2012 Feb;56(2):887-92. Epub 2011 Nov 28.

    PMID:
    22123705
    [PubMed - indexed for MEDLINE]
    13.

    In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine.

    Schader SM, Oliveira M, Ibanescu RI, Moisi D, Colby-Germinario SP, Wainberg MA.

    Antimicrob Agents Chemother. 2012 Feb;56(2):751-6. Epub 2011 Nov 28.

    PMID:
    22123692
    [PubMed - indexed for MEDLINE]
    14.

    Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.

    Benaboud S, Hirt D, Launay O, Pannier E, Firtion G, Rey E, Bouazza N, Foissac F, Chappuy H, Urien S, Tréluyer JM.

    Antimicrob Agents Chemother. 2012 Feb;56(2):857-62. Epub 2011 Nov 28.

    PMID:
    22123690
    [PubMed - indexed for MEDLINE]
    15.

    Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.

    Moss JA, Malone AM, Smith TJ, Kennedy S, Kopin E, Nguyen C, Gilman J, Butkyavichene I, Vincent KL, Motamedi M, Friend DR, Clark MR, Baum MM.

    Antimicrob Agents Chemother. 2012 Feb;56(2):875-82. Epub 2011 Nov 28.

    PMID:
    22123689
    [PubMed - indexed for MEDLINE]
    16.

    HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.

    Porter KA, Cole SR, Eron JJ Jr, Zheng Y, Hughes MD, Lockman S, Poole C, Skinner-Adams TS, Hosseinipour M, Shaffer D, D'Amico R, Sawe FK, Siika A, Stringer E, Currier JS, Chipato T, Salata R, McCarthy JS, Meshnick SR.

    Antimicrob Agents Chemother. 2012 Feb;56(2):995-1000. Epub 2011 Nov 28.

    PMID:
    22123685
    [PubMed - indexed for MEDLINE]
    17.

    Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women.

    Benaboud S, Tréluyer JM, Urien S, Blanche S, Bouazza N, Chappuy H, Rey E, Pannier E, Firtion G, Launay O, Hirt D.

    Antimicrob Agents Chemother. 2012 Feb;56(2):776-82. Epub 2011 Nov 21.

    PMID:
    22106227
    [PubMed - indexed for MEDLINE]
    18.

    Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.

    Else LJ, Douglas M, Dickinson L, Back DJ, Khoo SH, Taylor GP.

    Antimicrob Agents Chemother. 2012 Feb;56(2):816-24. Epub 2011 Nov 21.

    PMID:
    22106215
    [PubMed - indexed for MEDLINE]
    19.

    Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity.

    Henderson GJ, Lee SK, Irlbeck DM, Harris J, Kline M, Pollom E, Parkin N, Swanstrom R.

    Antimicrob Agents Chemother. 2012 Feb;56(2):623-33. Epub 2011 Nov 14.

    PMID:
    22083488
    [PubMed - indexed for MEDLINE]
    20.

    Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors.

    McFadden K, Fletcher P, Rossi F, Kantharaju, Umashankara M, Pirrone V, Rajagopal S, Gopi H, Krebs FC, Martin-Garcia J, Shattock RJ, Chaiken I.

    Antimicrob Agents Chemother. 2012 Feb;56(2):1073-80. Epub 2011 Nov 14.

    PMID:
    22083481
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk